v3.26.1
CONVERTIBLE LOANS AND WARRANTS AND ANTI-DILUTION LIABILITIES (Tables)
3 Months Ended
Mar. 31, 2026
Convertible Loans And Warrants And Anti-dilution Liabilities  
SCHEDULE OF FAIR VALUE RECURRING BASIS

The following table summarizes fair value measurements by level as of March 31, 2026 and December 31, 2025 measured at fair value on a recurring basis:

 

March 31, 2026  Level 1   Level 2   Level 3   Total 
   In U.S. dollars 
Assets                    
None    -     -     -     - 
                     
Liabilities                    
Convertible Loans (including long term)    -     -    878    878 
Derivative liability - Anti dilution rights    -     -    7,837     7,837 

 

and December 31, 2025  Level 1   Level 2   Level 3   Total 
   In U.S. dollars 
Assets                    
None   -    -    -    - 
                     
Liabilities                    
Convertible Loans
(including long term)
   -    -    901    901 
Derivative liability - Anti dilution rights   -    -    7,103    7,103 
SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE CHANGES

 

         
   Convertible Loans at Fair Value 
   March 31, 2026   December 31, 2025 
   $000 
Opening Balance, (including short term loans from related party which is also convertible)   901    4,163 
Conversion of convertible loan         (869)
Transition from amortized cost to convertible loans measured at fair value          
Change in fair value of convertible loans liability   (23)   (2,393)
Closing balance   878    901 
SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED

 

   As of March 31,   As of December 31, 
   2026   2025 
Expected term (in years)   1.92     2 
Expected average (Monte Carlo) volatility   

53

%   55.38%
Expected dividend yield   -     - 
Risk-free interest rate   3.78%   3.40%
WACC   27%   26%
SCHEDULE OF ANTI-DILUTION RIGHTS DERIVATIVE LIABILITY

 

           
   Anti-Dilution Liabilities at Fair value 
   March 31, 2026   December 31, 2025 
   $000 
Opening Balance   7,102    - 
Recognition of anti-dilution rights granted to new investors (see Note 6 – Capital raise)   329    7,102 
Fair value adjustment   406    - 
Closing balance   7,837    7,102